Department Of Pharmacology

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/108

Browse

Subject: search.filters.subject.diabetes

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Treatment of diabetic complications: do flavonoids holds the keys?
    (Taylor and Francis Ltd., 2023-07-12T00:00:00) Chalotra, Rishabh; Gupta, Tanya; Chib, Shivani; Amanat, Muhammed; Kumar, Puneet; Singh, Randhir
    Diabetes mellitus (DM) is an endocrinological disorder in which blood sugar levels get elevated and if unmanaged, it leads to several critical complications. Existing therapies or drugs are not able to attain absolute control of DM. Moreover, associated side/adverse effects associated with pharmacotherapy further worsen the Quality of life of patients. Present review is focused on therapeutical potential of flavonoids in management of diabetes and diabetic complications. Plenteous literature has established significant potential of flavonoids in the treatment of diabetes and diabetic complications. A number of flavonoids are found to be effective in treatment of not only diabetes but progression of diabetic complication was also found to be attenuated with the use of flavonoids. Moreover, SAR studies of some flavonoids also indicated the that efficacy of flavonoids is increased with a change in functional group of flavonoids in the treatment of diabetes and diabetic complications. A number of clinical trials are into action to investigate the therapeutic potential of flavonoids as first-line drugs or as adjuvants for treatment of diabetes and diabetic complications. Owing to their diverse mechanism of action, efficacy and safety, flavonoids may be conscripted as potential candidate for treatment of diabetic complications. � 2023 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Effect of dietary anthocyanins on biomarkers of type 2 diabetes and related obesity: A systematic review and meta-analysis
    (Taylor and Francis Ltd., 2023-03-13T00:00:00) Tiwari, Vandita; Sharma, Saloni; Tiwari, Apoorv; Sheoran, Bhawna; Kaur, Satveer; Sharma, Anjali; Yadav, Mona; Bhatnagar, Archana; Garg, Monika
    Anthocyanins have been reported for the protective effects against type 2 diabetes and related obesity. This meta-analysis examined the benefits of anthocyanins on type 2 diabetes and obesity biomarkers in animals and humans. The study included 21 clinical trials and 27 pre-clinical studies. A systematic search was conducted using the following inclusion criteria: in vivo rodent studies; human randomized clinical trials, both aimed at assessing the fasting blood glucose (FBG), HbA1c, total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein; and study duration of at least two weeks. Out of the 201 examined publications, 48 were shortlisted after implementation of the selection criteria. Results of clinical trials demonstrated that consumption of anthocyanin-rich food significantly reduced the FBG (p < 0.0001), HbA1c (p = 0.02), TC (p = 0.010), TG (p = 0.003), LDL (p = 0.05) and increases the HDL (p = 0.03) levels. Similarly, pre-clinical studies demonstrated the amelioration of the HbA1c (p = 0.02), FBG, TC, TG, and LDL (p < 0.00001), with non-significant changes in the HDL (p = 0.11). Sub-group analysis indicated dose-dependent effect. This compilation confirms that consuming anthocyanin-rich foods positively correlates with the reduction in the blood glucose and lipid levels in diabetic and obese subjects. � 2023 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review
    (Wolters Kluwer Medknow Publications, 2021-08-18T00:00:00) Bhattacharyya, Anusuya; Sarma, Phulen; Sharma, Dibya; Das, Karuna; Kaur, Hardeep; Prajapat, Manisha; Kumar, Subodh; Bansal, Seema; Prakash, Ajay; Avti, Pramod; Thota, Prasad; Reddy, Dibbanti; Gautam, Bhaswati; Medhi, Bikash
    Since the onset of COVID-19 pandemic, parallel opportunistic infections have also been emerging as another disease spectrum. Among all these opportunistic infection, mucormycosis has become a matter of concern with its rapid increase of cases with rapid spread as compared to pre-COVID-19 era. Cases have been reported in post-COVID-19-related immune suppression along with the presence of comorbidity which adds on the deadly outcome. There is no systematic review addressing the issue of COVID-19-Associated mucormycosis. This is the first systematic review of published studies of mucormycosis associated with COVID-19. The aim was to analyze the real scenario of the disease statement including all the published studies from first November 2019 to 30th June to analyze the contemporary epidemiology, clinical manifestations, risk factor, prognosis, and treatment outcome of COVID-19 associated rhino-orbito-cerebral-mucormycosis. A comprehensive literature search was done in following databases, namely, PubMed, Google Scholar, Scopus, and EMBASE using keywords mucormycosis, rhino orbital cerebral mucormycosis, COVID-19, and SARS-CoV-2 (from November 01, 2019 to June 30, 2021). Our study shows that, while corticosteroids have proved to be lifesaving in severe to critical COVID-19 patients, its indiscriminate use has come with its price of rhino-orbito-cerebral mucormycosis epidemic, especially in India especially in patients with preexisting diabetes mellitus with higher mortality. Corticosteroid use should be monitored and all COVID-19 patients should be closely evaluated/monitored for sequelae of immunosuppression following treatment. � 2021 Wolters Kluwer Medknow Publications. All rights reserved.